Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study | Zendy

Mette Charlot | Zendy; Lars Nielsen | Zendy; Jesper Lindhardsen | Zendy; Ole Ahlehoff | Zendy; A. M. Schjerning Olsen | Zendy; Mona Hansen | Zendy; Peter Riis Hansen | Zendy; Jan Kyst Madsen | Zendy; Lars Køber | Zendy; Gunnar Gislason | Zendy; Christian TorpPedersen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study

Author(s) -

Mette Charlot,

Lars Nielsen,

Jesper Lindhardsen,

Ole Ahlehoff,

A. M. Schjerning Olsen,

Mona Hansen,

Peter Riis Hansen,

Jan Kyst Madsen,

Lars Køber,

Gunnar Gislason,

Christian TorpPedersen

Publication year - 2012

Publication title -

european heart journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.336

H-Index - 293

eISSN - 1522-9645

pISSN - 0195-668X

DOI - 10.1093/eurheartj/ehs202

Subject(s) - medicine , clopidogrel , discontinuation , myocardial infarction , cardiology , platelet aggregation inhibitor , adverse effect , thrombosis , cohort , aspirin

The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated. We analysed the risk of adverse cardiovascular outcomes after discontinuation of 12 months of clopidogrel treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research